The price of the first domestic anti-coronavirus oral drug is initially set to be no more than 300 yuan

　　Guangzhou Daily News (All Media Reporter Tu Duanyu) On August 7, Henan True Biotechnology Co., Ltd. reported that: At present, the price of Azvudine tablets for the treatment of new coronary pneumonia has been initially determined, and each bottle is less than 300 yuan. Bottle of 35 tablets, 1mg per tablet.

On July 25, the State Food and Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the Drug Administration Law and in accordance with the special drug approval procedures, and approved Henan Zhenzhen Biotechnology Co., Ltd. Azvudine Tablets with conditions to increase the registration of new coronavirus pneumonia indications Application.

This means that Azvudine Tablet has become the first self-developed oral small molecule new crown treatment drug in China.

　　It is worth noting that as of the end of June this year, only two new crown small molecule drugs have been approved for marketing in the world.

One is Merck's Molnupiravir (Monapilavir) and the other is Pfizer's Paxlovid.

Among them, Paxlovid was approved by the State Food and Drug Administration of China for import in February this year. At present, the price of the latter in China is 2,300 yuan/box/course of treatment.

　　It is reported that shortly after the application for registration of Azvudine tablets was approved with conditions, Real Biology submitted a listing application to the Hong Kong Stock Exchange.

According to the prospectus, Real Biology has engaged an independent third party, Peking Union Medical College, to produce Azvudine.

In preparation for the commercialization of Azvudine, strategic agreements have been entered into with several leading pharmaceutical manufacturers in China, including Peking Union Medical College.

At the same time, Real Biology pointed out that it has its own production capacity with a total construction area of ​​22,262 square meters, with an annual production capacity of about 1 billion tablets of azvudine, and plans to seek to include azvudine in China's national medical insurance catalog.